Published in J Am Coll Cardiol on July 19, 2005
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (ORAR III) | NCT00552669
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol (2011) 3.71
The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03
Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv (2011) 1.85
Intravascular optical imaging technology for investigating the coronary artery. JACC Cardiovasc Imaging (2011) 1.42
The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol (2012) 1.35
Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab (2013) 1.13
Endothelial dysfunction after sirolimus-eluting stent placement. J Am Coll Cardiol (2005) 1.12
Endothelial dysfunction over the course of coronary artery disease. Eur Heart J (2013) 1.09
Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release (2008) 0.95
Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model. J Biomed Biotechnol (2012) 0.94
Late stent thrombosis, endothelialisation and drug-eluting stents. Neth Heart J (2009) 0.91
Application of response surface methodology in development of sirolimus liposomes prepared by thin film hydration technique. Bioimpacts (2013) 0.88
A patient with repeated catastrophic multi-vessel coronary spasm after zotarolimus-eluting stent implantation. Korean Circ J (2013) 0.88
Impact of an endothelial progenitor cell capturing stent on coronary microvascular function: comparison with drug-eluting stents. Korean J Intern Med (2014) 0.87
Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. Clin Res Cardiol (2013) 0.87
Novel drug-eluting stents in the treatment of de novo coronary lesions. Vasc Health Risk Manag (2011) 0.85
Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol (2011) 0.84
High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation. PLoS One (2014) 0.84
Coronary stent healing, endothelialisation and the role of co-medication. Neth Heart J (2007) 0.83
Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome. Int J Cardiovasc Imaging (2016) 0.82
Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation. Heart Vessels (2017) 0.82
The effects of bare metal versus drug-eluting stent implantation on circulating endothelial cells following percutaneous coronary intervention. J Res Med Sci (2011) 0.80
Rapamycin impairs endothelial cell function in human internal thoracic arteries. Eur J Med Res (2015) 0.80
Bioresorbable vascular scaffolds - basic concepts and clinical outcome. Nat Rev Cardiol (2016) 0.78
Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.78
Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. Int J Cardiovasc Imaging (2013) 0.78
Poly-l-lactic acid/amorphous calcium phosphate bioabsorbable stent causes less inflammation than poly-l-lactic acid stent in coronary arteries. Int J Clin Exp Med (2014) 0.77
Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovasc Disord (2016) 0.77
Elevated high sensitive C-reactive protein and apelin levels after percutaneous coronary intervention and drug-eluting stent implantation. J Zhejiang Univ Sci B (2010) 0.76
The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc Disord (2015) 0.76
Relationship between endothelial vasomotor function and strut coverage after implantation of drug-eluting stent assessed by optical coherence tomography. Int J Cardiovasc Imaging (2013) 0.75
Increase in coronary microvascular resistances after recanalisation with drug-eluting stent. Comput Methods Biomech Biomed Engin (2014) 0.75
Drug-eluting stents not for all patients. Neth Heart J (2006) 0.75
Coronary vasospasm-induced periodic ventricular fibrillation and successful ablation through coronary stenting. Postepy Kardiol Interwencyjnej (2015) 0.75
Acute two-vessel occlusion due to simultaneous very late stent thrombosis following sirolimus-eluting stent implantation: a case report and review of the literature. Postepy Kardiol Interwencyjnej (2015) 0.75
Coronary vasomotion dysfunction after everolimus-eluting stent implantation. Interv Med Appl Sci (2014) 0.75
Simultaneous very late stent thrombosis in multiple coronary arteries. Tex Heart Inst J (2012) 0.75
Drug-eluting stents for all patients. Neth Heart J (2006) 0.75
Endothelial dysfunction after drug-eluting stent was never predicted in preclinical studies. J Am Coll Cardiol (2006) 0.75
Life-threatening coronary artery spasm following sirolimus-eluting stent deployment. J Am Coll Cardiol (2006) 0.75
Factors associated with cardiovascular target organ damage in children after renal transplantation. Pediatr Nephrol (2017) 0.75
Coronary Artery Aneurysms: A Review of the Epidemiology, Pathophysiology, Diagnosis, and Treatment. Front Cardiovasc Med (2017) 0.75
The dawn of neurosurgery in pre-conquest Mesoamerican territories. Childs Nerv Syst (2017) 0.75
[Coronary stent thrombosis: what's new in 2011?]. Herz (2011) 0.75
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med (2002) 6.37
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol (2007) 3.82
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol (2006) 3.07
Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv (2011) 2.67
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54
Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol (2005) 2.47
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43
Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail (2012) 2.41
Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol (2004) 2.30
Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol (2005) 2.19
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17
Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol (2010) 2.16
Collateral-flow measurements in humans by myocardial contrast echocardiography: validation of coronary pressure-derived collateral-flow assessment. Eur Heart J (2005) 2.12
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11
25 years of coronary angioplasty: almost a fairy tale. Lancet (2003) 2.09
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA (2006) 2.06
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Clinical relevance of coronary angiography at the time of percutaneous closure of a patent foramen ovale. Catheter Cardiovasc Interv (2007) 2.03
Is alcohol ablation of the septum associated with recurrent tachyarrhythmias? Swiss Med Wkly (2007) 2.01
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99
Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol (2002) 1.92
Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J (2004) 1.91
Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation (2007) 1.90
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam Study. Am Heart J (2010) 1.87
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol (2011) 1.86
Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv (2012) 1.84
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis (2011) 1.84
Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation (2003) 1.83